6 results about "Asthma treatment" patented technology

The present invention relates to a biomarker for predicting an asthma treatment response to a biological agent and a use thereof, and specifically to a method for predicting an asthma treatment effect

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The present application relates to the field of intelligent medical auxiliary decision-making technology, and discloses a ladder treatment scheme recommendation method based on asthma control level and drug response phenotype. The present application aims to solve the problem that the existing scheme cannot identify the deep reason of uncontrolled condition, leading to blind step-up treatment. The present application excludes non-compliance interference by checking the drug execution rate, and improves the authenticity of condition assessment. The present application uses environmental exposure characteristics to adaptively correct the exhaled nitric oxide determination threshold, and eliminates the deviation of smoking on inflammation recognition. The present application combines the logic tree voting of multi-dimensional biological indicators to lock the drug response phenotype. Finally, based on the double index of condition state and phenotype, the present application locates the upgrade or transformation treatment path and generates a recommended scheme. The present application realizes the precise typing and differentiated drug administration of asthma treatment, effectively reduces the drug exposure risk of hormone-insensitive patients while ensuring the clinical efficacy.

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

The application discloses a soft capsule of Phellodendri fruit oil, a preparation method thereof and pharmaceutical use, and belongs to the technical field of biological medicines. The application extracts the Phellodendri fruit oil from Phellodendri fruit by using a supercritical CO2 extraction technology, refines the Phellodendri fruit oil by combining with molecular distillation, and obtains high-purity active ingredients with a myrcene content of greater than or equal to 8 mg / g; the soft capsule of the Phellodendri fruit oil is prepared by optimizing the proportion of accessories and a gradient drying process. Each soft capsule contains 100-500 mg of the Phellodendri fruit oil, the content particle size D90 is less than or equal to 30 microns, and the myrcene retention rate is greater than or equal to 90% after an accelerated test for three months. Pharmacodynamic studies show that the soft capsule of the Phellodendri fruit oil prepared by the application has a significant cough-relieving and phlegm-removing effect. The preparation process is advanced, the product quality is stable, and the application provides a cough and asthma treatment medicine with simple components and controllable quality for clinical use.